Commercial End Drug Shortages Alliance welcomes new member in Zydus...

End Drug Shortages Alliance welcomes new member in Zydus Pharmaceuticals (USA) Inc


Zydus Pharmaceuticals joined a union of diverse participants to address the issue of drug shortages in the US, the company announced. This new alliance is called the End Drug Shortages Alliance, which offers a platform for the key stakeholders to strategically focus on an important issue of healthcare, the shortages of drugs that disturb patient care.

Zydus Pharmaceuticals is the subsidiary and generic drug division of Zydus Lifescience Ltd. It was founded in 2003 and is headquartered in Pennington, New Jersey. The company claims that  it has been steadfast in its goal to provide service, innovation and quality since the beginning. Zydus Pharmaceuticals offers above 485 SKUs as of today and is ranked fifth in the largest unbranded generic corporations in the country based on fulfilled prescriptions.

The holding company of Zydus Pharmaceuticals, Zydus Group is a global life sciences company that works on the discovery, development, manufacturing and marketing of a wide range of products in the healthcare therapy spectrum. The company’s mission is to discover new potential opportunities in life sciences using healthcare solutions of top quality and hence impact lives positively. To work on this mission, the group has over 23,000 employees globally.

The End Drugs Shortages Alliance is a group consisting of the select supply chain, industry, and health systems among other stakeholders devoted to rectifying the supply challenges being faced by the pharmaceutical industry in the U.S. that is causing instability in the access to vital medication. The group also includes distributors, manufacturers and group purchasing organizations, which are directly working on the supply of the medicines. The alliance gives utmost importance to initiatives that emphasize on quality, redundancy, transparency and production of extra supply to attain access to the essential medicines for patients without any disruption in the flow of products.

Speaking on the news, Managing Director of Zydus Lifesciences Ltd., Dr. Sharvil Patel said, “Through our innovations and patient-centric approach, we have been committed to providing novel solutions to address unmet healthcare needs of the patients. Providing access to medicines is an important part of our core purpose which is to empower people with the freedom to live healthier and more fulfilled lives.” He further mentioned that partnering with diverse stakeholders as they did with this alliance will take them closer to this goal.

CEO of Zydus Pharmaceuticals, Michael Keenley said that patients and their families are being affected by the drug shortages and as a member of the alliance, the company will plan on how to work around the problems that contribute to the shortage of drugs.

The aim of the alliance is to improve medication accessibility by creating a more transparent market for the participants, which will lead to a better quality of manufactured medicines as well as more supply.

Division Chair of Pharmacy Supply Solution for Mayo Clinic and Chair for the Alliance Advisory Board, Eric Tichy, expressed happiness to have Zydus Pharmaceuticals in the alliance to end shortages of drugs. He believes that such partnerships between the organizations reinforces their ability to make a difference in the patients’ quality of life by improving the quality and supply of the medications.

Latest news

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Duchenne Muscular Dystrophy Fails to Show Functional Improvement

Pfizer's gene therapy for Duchenne muscular dystrophy failed to improve motor function in young boys in a key late-stage...

Phase 3 Trial Results for Loqtorzi Show Positive Results in Advanced Hepatocellular Carcinoma Patients

Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show that in first-line patients suffering from advanced hepatocellular...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you